These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 14686228)

  • 1. Costs and consequences of cytomegalovirus disease.
    Schnitzler MA
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S5-8. PubMed ID: 14686228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost advantages of oral drug therapy for managing cytomegalovirus disease.
    Somerville KT
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S9-12. PubMed ID: 14686229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
    Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New prophylactic treatment strategy for cytomegalovirus disease.
    Lake KD
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S13-6. PubMed ID: 14686230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulary considerations for drugs used to prevent cytomegalovirus disease.
    Pescovitz MD
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S17-21. PubMed ID: 14686231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
    J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
    Mauskopf JA; Richter A; Annemans L; Maclaine G
    Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
    Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
    Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
    Gane E; Saliba F; Valdecasas GJ; O'Grady J; Pescovitz MD; Lyman S; Robinson CA
    Lancet; 1997 Dec; 350(9093):1729-33. PubMed ID: 9413463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
    Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
    Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
    Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.